Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity
Endocrinology, Diabetes & Metabolism Case Reports · 01.04.2026 · 2026 (2)
DOI: 10.1530/edm-26-0002 ↗Kurz gefasst
Fallbericht in der Zeitschrift Endocrinology, Diabetes & Metabolism Case Reports, online erschienen am 01.04.2026. Verfasst von Hiroki Takizawa und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Kido Hospital, Niigata, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
We report three obese patients with type 2 diabetes and alcohol-associated liver disease (ALD), including one patient with alcohol use disorder, who exhibited reduced alcohol intake after the initiation of tirzepatide. Although tirzepatide has shown beneficial effects on liver fibrosis in metabolic dysfunction-associated steatohepatitis, its effect on ALD or alcohol intake has not been reported. After the initiation of tirzepatide, all patients demonstrated decreased alcohol consumption, improved liver function, and better metabolic control. These findings suggest that tirzepatide can provide additional benefits for ALD by reducing alcohol intake while improving metabolic risk factors, potentially offering a novel therapeutic option for this high-risk population. Learning points
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Kido Hospital, Niigata, Japan.
- Department of Internal Medicine, Niigata University Faculty of Medicine, Niigata, Japan.
- Department of Psychiatry, Kohdo Hospital, Niigata, Japan.
ORCID-Profile: Hiroki Takizawa
Zitieren
APA
Takizawa, H., Tsuda, A., Suriki, H., & Amagane, H. (2026). Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity. Endocrinology, Diabetes & Metabolism Case Reports, 2026(2). https://doi.org/10.1530/edm-26-0002
Vancouver
Takizawa H, Tsuda A, Suriki H, Amagane H. Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity. Endocrinology, Diabetes & Metabolism Case Reports. 2026;2026(2). doi:10.1530/edm-26-0002
BibTeX
@article{Takizawa2026,
author = {Takizawa, Hiroki and Tsuda, Akiko and Suriki, Hidehisa and Amagane, Hideki},
title = {Tirzepatide reduced alcohol use in three patients with alcohol-associated liver disease, type 2 diabetes, and obesity},
journal = {Endocrinology, Diabetes & Metabolism Case Reports},
year = {2026},
volume = {2026},
number = {2},
doi = {10.1530/edm-26-0002}
}
EUVIMED